Anthropic Acquires Coefficient Bio, Expands AI Focus in Life Sciences

Anthropic’s $400M acquisition of Coefficient Bio highlights a strategic push into AI-powered drug discovery and emerging life sciences innovation.

Anthropic has acquired stealth biotech startup Coefficient Bio in a deal reportedly valued at around $400 million in stock, according to multiple reports. The move marks a significant step in the company’s expansion into healthcare and life sciences, as it looks to apply artificial intelligence to biological research and drug discovery.

Coefficient Bio, founded just eight months ago by former Genentech researchers Samuel Stanton and Nathan C. Frey, was focused on building AI models to improve efficiency in drug discovery and related scientific processes. The startup operated with a small team of around 10 people, who are expected to join Anthropic’s health and life sciences division following the acquisition.

The deal comes as Anthropic continues to expand its presence in the scientific research space. In October, the company introduced Claude for Life Sciences, a tool designed to assist researchers in accelerating discovery and analysis. The acquisition of Coefficient Bio adds specialized expertise in computational biology, strengthening Anthropic’s capabilities in applying AI to complex scientific domains.

ALSO READ: Co-Founder Jack Clark to Lead Anthropic’s New AI Institute

Reports suggest that the startup was backed in part by venture firm Dimension and had been working on advanced AI models aimed at improving how biological systems are studied. While details remain limited, the focus on early-stage, high-potential research teams indicates a strategy centered on talent acquisition and long-term innovation rather than immediate product deployment.

The development reflects a broader trend across the AI industry, where companies are increasingly exploring applications beyond traditional software use cases. Healthcare and life sciences have emerged as key areas of interest, given the potential for AI to accelerate drug discovery, reduce costs and improve research outcomes.

ALSO READ: Pentagon Questions Anthropic on Claude’s Military Use

As competition intensifies, companies like Anthropic are positioning themselves not only as model providers but also as contributors to scientific advancement, highlighting a shift toward deeper integration of AI into research-intensive industries.

Disclaimer: This report is based on information reported by TechCrunch. NervNow has not independently verified the claims.

MORE ON ANTHROPIC/CLAUDE
Federal Judge Blocks Trump’s Pentagon Ban on Anthropic’s AI Models
Anthropic’s Free Courses With Certificates
Microsoft’s New $99 Frontier Suite Brings Claude Into Copilot
Banned by the Pentagon, Claude Hit No. 1 on App Store